Vical, Inc. (NASDAQ:VICL)

CAPS Rating: 4 out of 5

The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Results 1 - 20 of 28 : 1 2 Next »

Recs

1
Member Avatar zzlangerhans (99.81) Submitted: 3/28/2015 3:58:17 AM : Outperform Start Price: $0.90 VICL Score: +3.10

Vical seems determined to bust my portfolio as I keep adding shares as the share price withers. Despite the horrendous chart, I find Vical appealing in 2015 as they have continued to progress their clinical trials to the point where topline data from the phase I/II trial of HSV vaccine is expected in mid 2015. Enrollment in the ASP0113 kidney transplant trial should be compelted in mid 2015 and in the ASP0113 HCT trial by the end of 2015. The market cap is about 84M and as of the end of 2014 the company had 49M cash, with a controlled burn of about 3M per quarter. I terminated my previous outperform for a substantial loss in order to enter a new green thumb with an updated pitch and a shot at a multibagger score. The zzporte portfolio has 30000 shares with cost basis 1.04, so we're down a few thousand but I wouldn't rule out adding another 10000 below 0.8.

Recs

0
Member Avatar stemcells2011 (91.27) Submitted: 3/3/2015 10:39:25 AM : Outperform Start Price: $1.00 VICL Score: -4.34

Approaching book value (.62 cent)

Seems to have plenty cash. Possible catalyst ahead could drive it up.

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 3/18/2014 7:03:47 PM : Outperform Start Price: $1.32 VICL Score: -33.37

prediction TOS

Recs

0
Member Avatar 10qdetective (82.15) Submitted: 3/4/2014 1:45:46 AM : Outperform Start Price: $1.51 VICL Score: -48.60

Potential buyer in Merck?

Vical (VICL) is developing Allovectin, a first-in-class investigational DNA-based immunotherapeutic designed to stimulate both innate and adaptive immune responses in local tumors and distal metastases.

Of unique interest to Merck is that this immunotherapy is currently being evaluated in late-stage clinical trials as first-line treatment for Stage III and IV melanoma. Merck watchers might want to know, too, that Vical’s current CEO, Vijay Samant, previously spent 20 years with Merck in international sales and marketing.

Recs

0
Member Avatar paigecoverdale (< 20) Submitted: 1/13/2014 3:38:31 PM : Outperform Start Price: $1.32 VICL Score: -43.42

Doubler

Recs

1
Member Avatar AndrewGreenBull (99.15) Submitted: 12/18/2013 11:37:30 AM : Outperform Start Price: $1.05 VICL Score: -26.87

With 2 approved products, a robust pipeline and 55 millions cash, VICL is a steal at current price $1.04.

Dengue Vaccine data will be released in this month according to ClinicalTrial. Should be back to $2 in days.

Recs

1
Member Avatar Rilac (98.29) Submitted: 9/5/2013 4:48:36 PM : Outperform Start Price: $1.50 VICL Score: -60.28

Vical is posed for a pullback as the dates for their clinical trials in phase2/3 studies nears

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 5:22:16 PM : Underperform Start Price: $1.35 VICL Score: +56.89

Short. Revenues declining. POS biotech.

Recs

0
Member Avatar stainsolution (86.32) Submitted: 4/9/2012 7:42:06 PM : Outperform Start Price: $3.17 VICL Score: -121.09

Bio play

Recs

0
Member Avatar RBuskey106 (63.92) Submitted: 3/14/2012 10:43:51 PM : Outperform Start Price: $3.36 VICL Score: -120.43

Biotech play. Like the story.

Recs

0
Member Avatar CATMANF800 (< 20) Submitted: 12/3/2011 2:51:12 PM : Outperform Start Price: $4.78 VICL Score: -144.28

Technicals

Recs

0
Member Avatar vaderblue (< 20) Submitted: 11/23/2011 4:24:47 PM : Outperform Start Price: $3.45 VICL Score: -151.44

I feel Vical will outperform with needed cash coming from a vaccine recently licensed to Astellas Pharna of Japan. This will improve their revenue as well as the
balance sheet. A hurdle over the hump. I can see
$5 or more within two quarters. Go go long.

Recs

0
Member Avatar qasamm (42.66) Submitted: 4/5/2011 2:32:51 PM : Outperform Start Price: $2.97 VICL Score: -124.07

Pipeline, pipeline, pipeline- the 3 Ps!

Recs

0
Member Avatar drivermike64 (86.22) Submitted: 3/14/2011 1:36:28 AM : Outperform Start Price: $2.42 VICL Score: -121.13

biotech with promising cancer drug in stage III trials

Recs

0
Member Avatar chimpcontest (< 20) Submitted: 2/21/2011 2:11:28 PM : Outperform Start Price: $1.89 VICL Score: -106.48

BlackSwanCapital haiku

Third phase data soon

immunotherapeutic

a wunderkind drug

Recs

0
Member Avatar DudeManBroChief (< 20) Submitted: 9/30/2010 12:32:13 PM : Outperform Start Price: $2.21 VICL Score: -139.77

Look for this stock to spike in mid-2011 before results are revealed for the phase III trial of Allovectin-7 in melanoma.

Recs

0
Member Avatar BicaChica (80.31) Submitted: 9/29/2010 10:11:54 PM : Outperform Start Price: $2.26 VICL Score: -139.15

tenmiles

Recs

0
Member Avatar leebest1a (< 20) Submitted: 8/1/2010 3:51:11 PM : Outperform Start Price: $3.40 VICL Score: -158.04

VICL

Recs

0
Member Avatar Biotech2010 (43.80) Submitted: 1/26/2010 8:50:26 PM : Outperform Start Price: $2.91 VICL Score: -158.18

@3.41

Recs

0
Member Avatar colbob2 (< 20) Submitted: 12/3/2009 5:22:50 PM : Outperform Start Price: $2.90 VICL Score: -153.52

AS A PHARMACIST I FEEL THE FUTURE IN DRUGS IS IN THE VACINE FIELD, WHICH VICL EXCELS. WITH MONEY FROM MERCK, AND SNY. I FEEL THAT THIS STOCK WILL MOVE UP NEXT YEAR AND FEEL THAT THE SELL OFF THAT IS NOW GOING ON IS A TAX RELIEF SELL OFF.

Results 1 - 20 of 28 : 1 2 Next »

Featured Broker Partners


Advertisement